PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer. - Wikidata - wikimedia - TriplyDB

PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.

PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.

http://www.wikidata.org/entity/Q34454922

about

Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy Relevance of tumor-infiltrating lymphocytes in breast cancer Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis.PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.Novel therapeutic strategies for patients with triple-negative breast cancer Clinical significance of tumor-infiltrating lymphocytes in breast cancer Emerging therapies for breast cancer Targeting programmed cell death ligand 1 by CRISPR/Cas9 in osteosarcoma cells.Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.The immune microenvironment of breast ductal carcinoma in situ.Prevalence and predictors of androgen receptor and programmed death-ligand 1 in BRCA1-associated and sporadic triple-negative breast cancer.New Immunotherapy Strategies in Breast Cancer.PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis.RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors Emerging therapeutic targets in metastatic progression: A focus on breast cancer.PD-L1 polymorphism can predict clinical outcomes of non-small cell lung cancer patients treated with first-line paclitaxel-cisplatin chemotherapy.Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast Cancer Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.Programmed death-ligand 1 expression in rectal cancer.The Role of PD-L1 Expression and Intratumoral Lymphocytes in Response to Perioperative Chemotherapy for Urothelial Carcinoma.Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer.Nuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.Breast cancer and immunology: biomarker and therapeutic developments.Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.PD-L1 expression and the immune microenvironment in primary invasive lobular carcinomas of the breast.Potential biomarker for checkpoint blockade immunotherapy and treatment strategy.VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer.Immunotherapy for breast cancer: past, present, and future.Chemotherapy remains an essential element of personalized care for persons with lung cancers.Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.

P2860

Q26745444-6C97B22D-C506-4E26-A73C-F920E96CC801 Q26747792-E8F80069-735A-4C1B-B215-4FFD4E00CFA4 Q26779184-9A432A8F-3CAC-4A82-8256-2055295815BC Q26795598-536A2E96-4DB6-4FB1-BB4D-8CB3EAF3E325 Q27311085-19C2F762-3EA9-442E-A90A-AEE4543ED71B Q27853205-D66A9F23-16B1-4295-90E8-91F8274C0EEF Q27853376-86C237FC-F66A-4B73-A287-9DA7B3252556 Q28067436-F758E508-26DC-4543-BABB-8E287B1F2830 Q28070214-913BE802-89FE-4E63-A6DB-F2673C8140B4 Q33617949-AF779421-7296-4DF4-A395-C0CC241B0709 Q33728298-1CE5E590-B341-4FD3-8191-8D8D6A8A61E9 Q33769821-A2356110-3134-4C36-8C54-549AACD1BECE Q33834968-382F8120-CEE4-4CAE-987C-572B2A6633ED Q33915040-90D40190-7A7B-499D-BE4D-DC49DBF931C2 Q34549227-C4D1E180-116D-4DEA-B4AC-B6699A8CF26D Q35955369-5754F05D-A241-4255-986C-5B7C3FD4B752 Q36030084-C21FDAB7-3237-4783-AA2F-44908194F634 Q36693087-128DEC2B-BD60-43AF-B1D1-8ED712D9AE0A Q36854062-4501B199-1FBB-43C0-B7C1-61103591CA32 Q36903206-FBEDCF3C-E012-4486-BB29-8BF4E257B46F Q36963025-47D315CE-1E4B-4650-A55E-18BB3C745DAD Q37125088-E13E3056-D6E5-43CD-B03A-239777CC0D3B Q37316596-D0DA6269-5403-4953-9CA6-294666844C8A Q37462524-85413484-4756-4315-9C17-D5C7969DE0E7 Q37470361-8CAC71E1-B978-4CF5-A8D4-3BF77E6D21F2 Q37474092-BE16856E-B9DC-43E0-81AF-FBAB67D1024C Q37515182-39872937-AB10-426B-A23B-AB1B51E82559 Q37530339-E4FD140A-EDD3-4BFE-B479-2A3328FE591E Q37616487-8ADF9F26-406D-4B3B-B058-1F457DEA2E02 Q37713503-EEE04038-9CA9-4C67-9118-228DDBBAFE8C Q37716582-90FFA2D3-C4B5-4273-9BA5-411E2773A211 Q38584383-F2AA9BDD-1F75-4A14-ACD9-98F914EB0A78 Q38629357-7D8CE3D6-6831-4DE4-BB00-A70A37376428 Q38668389-D5551E69-9D30-4AA8-B47A-CCA33895B342 Q38700735-5C27F52D-80B6-4370-A355-5547C748DEE9 Q38710357-5C40FFE8-6161-46B7-A042-BC0B5DD8DE8C Q38754407-FFDFC284-4EBD-42D9-9C7E-120FBAE14036 Q38787696-80EF1EED-35E0-4AA5-9ED2-56277443773E Q38838014-0CF83096-3FA4-40D3-B3E9-F538769A4471 Q38838643-B3E8019E-76C4-498C-AD93-F9DA0087B7BE

P2860

PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer.

http://www.wikidata.org/entity/Q34454922

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

PD-L1 Expression Correlates wi ...... Chemotherapy in Breast Cancer.

@ast

PD-L1 Expression Correlates wi ...... Chemotherapy in Breast Cancer.

@en

PD-L1 Expression Correlates wi ...... Chemotherapy in Breast Cancer.

@nl

type

label

PD-L1 Expression Correlates wi ...... Chemotherapy in Breast Cancer.

@ast

PD-L1 Expression Correlates wi ...... Chemotherapy in Breast Cancer.

@en

PD-L1 Expression Correlates wi ...... Chemotherapy in Breast Cancer.

@nl

prefLabel

PD-L1 Expression Correlates wi ...... Chemotherapy in Breast Cancer.

@ast

PD-L1 Expression Correlates wi ...... Chemotherapy in Breast Cancer.

@en

PD-L1 Expression Correlates wi ...... Chemotherapy in Breast Cancer.

@nl

P1433

Q34454922-4D110C09-3F73-40D8-BE15-B6A7B3153660

P1476

Q34454922-16892C77-4DBC-4B9C-8CF1-4D0E5BF9E8BD

P2093

Q34454922-02F0C722-4C7E-4678-AC5C-79230D7BB3B6

Q34454922-0E336B19-7EC1-4D98-8C9F-18D2EF11F707

Q34454922-38D4B22A-C85B-4768-BA32-B9C9B1896938

Q34454922-6CF515DD-85A5-40D6-8761-B0D66F1CA263

Q34454922-8F7426B9-F17E-4196-869E-22E96EFE4E76

Q34454922-A30F3F7C-D493-416A-892A-1FAEF03F5470

Q34454922-AEC1F0AC-1984-4939-959E-CB382B61EE0D

Q34454922-E8C8D6ED-9744-449E-82AB-36D151115870

Q34454922-F45E9BBB-D235-468D-A96F-6561AA933F99

P2860

Q34454922-09788565-2819-4CF2-8A6F-97DBC4918802

Q34454922-10A3D131-251B-4DC7-8A2E-F3E93650D83E

Q34454922-1422E6F8-BDA1-4C92-A45A-C712BF50EBA6

Q34454922-15EC0EFE-B6ED-47AB-9289-E0DD08C52EBB

Q34454922-37A3A37C-EC59-4432-B065-2A92A059078A

Q34454922-3E1809F0-0E9B-4ADD-8911-497BB5A736DC

Q34454922-4012DEAC-EBA2-4D03-B760-D8B380093089

Q34454922-45BB1046-BA39-481B-856C-B3A232F7D0A0

Q34454922-46E4CC00-6277-41EC-A47C-3349ACB17291

Q34454922-4B2F5D84-CE8F-4933-8951-7892DDCBF11F

P304

Q34454922-0D692BA5-5067-4E14-A622-CFC5F6F40E0C

P31

Q34454922-B3FF4B8D-D575-4FA7-85FC-F631653A39B4

P356

Q34454922-08E4593E-D044-4D98-9C84-C89786040CC9

P433

Q34454922-979DA940-0181-4A8D-83B9-FDBB3E57A5EF

P478

Q34454922-C028941B-06C9-4E37-A567-93C5C86CBDBF

P50

Q34454922-9DFCA0E6-51EB-4400-A255-86BE41FAFF12

P577

Q34454922-6803CA59-242F-44F7-A449-9A5DC61696AD

P698

Q34454922-8B96EFA8-762B-4204-B831-3BDE7502A32B

P921

Q34454922-0214AC4D-4E7D-431C-9F4A-179BBEE9BE3E

P932

Q34454922-055B223D-059F-4762-BA57-D4530BA2F984

P356

2326-6066.CIR-14-0133

P1433

Cancer immunology research

P1476

PD-L1 Expression Correlates wi ...... Chemotherapy in Breast Cancer.

@en

P2093

Christian Nixon

http://www.w3.org/2001/XMLSchema#string

David L Rimm

http://www.w3.org/2001/XMLSchema#string

Donald R Lannin

http://www.w3.org/2001/XMLSchema#string

Hallie Wimberly

http://www.w3.org/2001/XMLSchema#string

Herbert Haack

http://www.w3.org/2001/XMLSchema#string

Jason R Brown

http://www.w3.org/2001/XMLSchema#string

Lajos Pusztai

http://www.w3.org/2001/XMLSchema#string

Matthew R Silver

http://www.w3.org/2001/XMLSchema#string

Veerle Bossuyt

http://www.w3.org/2001/XMLSchema#string

P2860

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy.

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.

Programmed death ligand-1 expression in non-small cell lung cancer.

P304

326-332

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2326-6066.CIR-14-0133

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Kurt A Schalper

P577

2014-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25527356

http://www.w3.org/2001/XMLSchema#string

P921

P932

4390454

http://www.w3.org/2001/XMLSchema#string